J
Jean E Mulder
Researcher at Harvard University
Publications - 4
Citations - 531
Jean E Mulder is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Rate ratio. The author has an hindex of 3, co-authored 4 publications receiving 481 citations.
Papers
More filters
Journal ArticleDOI
Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study.
Charles A. Sklar,Ann C. Mertens,Pauline Mitby,John Whitton,Marilyn Stovall,Catherine E. Kasper,Jean E Mulder,Daniel M. Green,H. Stacy Nicholson,Yutaka Yasui,Leslie L. Robison +10 more
TL;DR: The results of this study will facilitate counseling current survivors about their future risk of premature menopause and aid in designing new regimens that seek to diminish late ovarian toxicity.
Journal ArticleDOI
Bone density in survivors of childhood cancer.
Jean E Mulder,John P. Bilezikian +1 more
TL;DR: The impact of cancer and cancer therapy on bone mineral density in survivors of childhood cancer is examined to assess the long-term adverse effects on endocrine systems.
Journal ArticleDOI
Virtual visits as long-term follow-up care for childhood cancer survivors: Patient and provider satisfaction during the COVID-19 pandemic.
Lisa B. Kenney,Lisa B. Kenney,Lynda M. Vrooman,Lynda M. Vrooman,Eileen Lind,Eileen Lind,Jill Brace-O'Neill,Jill Brace-O'Neill,Jean E Mulder,Larissa Nekhlyudov,Larissa Nekhlyudov,Christopher J. Recklitis,Christopher J. Recklitis +12 more
TL;DR: In this paper, the authors surveyed providers at an institution about their satisfaction with video-conference virtual visits (VVV) with 81 CCS during COVID-19 restrictions and found that CCS rated VV "as/nearly as" helpful as in-person visits (66%) and 82% prefer VV remain an option postpandemic.
Journal ArticleDOI
Thyroid late effects after treatment of childhood sarcoma
TL;DR: This was an evaluation of participants enrolled in LESS (Late Effects Surveillance System), a prospective, multicenter study of pediatric patients who had received radiotherapy and/or chemotherapy for primary Ewing’s sarcoma, osteosarcoma or soft-tissue Sarcoma.